Implications of shared motor and perceptual activations on the sensorimotor cortex for neuroprosthetic decoding.
Alexander B Silva, Jessie R Liu, Vanessa R Anderson...
https://pubmed.ncbi.nlm.nih.gov/40343020/Actively Recruiting
Led by Karunesh Ganguly · Updated on 2026-05-05
3
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are exploring the use of electrocorticography ECoG signals to control complex devices for motor and speech functions in adults who have severe neurological disorders such as ALS, spinal cord injury, stroke, multiple sclerosis, and muscular dystrophies. This study aims to determine if brain signals recorded directly from the brains surface can be used to operate robotic systems and generate speech, providing new communication and neuroprosthetic options for affected individuals. Participants will use a high-performance ECoG-based neural interface involving subdural cortical electrodes combined with the Blackrock NeuroPort Array device. The study involves training and assessing participants ability to control a robotic system and produce speech via brain signals. The intervention is device-based, and follow-up includes a long-term monitoring period of up to 6 years after implantation to track safety and functional outcomes. During the study, participants will undergo neurological assessments and training with the ECoG device. Researchers will monitor safety by tracking treatment-emergent adverse events and evaluate the primary and secondary objectives related to motor and speech control capabilities. The study includes regular follow-up visits over several years to assess device performance, participant function, and tolerability of the implant. Total participation may last up to 6 years post-implantation for ongoing safety and efficacy evaluation.
CONDITIONS
ECoG BMI for Motor and Speech Control
A
Adelyn Tu-Chan
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Karunesh Ganguly
Lead Sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational ECoG BCI | Standard eye‑tracking devices |
|---|---|---|
| What it is | An implanted electrocorticography (ECoG) brain–computer interface combining PMT subdural electrodes and the Blackrock NeuroPort system, tested for motor and speech control. | Eye‑tracking systems that enable communication by tracking gaze and selecting letters on a screen are the current standard assistive technology for individuals with severe paralysis. |
| Role in trial | Delivered as the single investigational intervention in a feasibility device study. | Not tested in this trial, provided for external context. |
| Primary use | Intended to restore communication and motor control for participants with severe paralysis. | Used to facilitate communication by allowing users to select letters or commands using eye movements. |
| How it is given or performed | Surgically implanted cortical electrodes record neural activity decoded to enable motor or speech control. | Non‑invasive device placed near the face that tracks eye gaze to control on‑screen selections. |
| Evidence status | Feasibility being evaluated; long‑term safety and efficacy not yet established. | Proven ability to support communication across many users over years. |
| Important risks | Risks include surgical implantation such as infection, device failure, or neural tissue reaction. | Minimal physical risk; potential for eye strain or fatigue over prolonged use. |
| Important limitations | Early‑stage feasibility with very small sample; long follow‑up needed to assess performance over years. | Requires reliable eye movement and may be slow, tiring, or hard to use in some environments or with advanced disease. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Not specified
Participants undergo implantation of the PMT/Blackrock Combination Device, which involves placing electrodes on the surface of the brain for neural signal recording.
1 surgical visit (in-person)
Duration - Not specified
Participants receive training and assessment on controlling a complex robotic system using the implanted ECoG-based neural interface and testing the ability to produce speech from brain signals.
Multiple training and assessment visits (in-person)
Duration - Up to 6 years post-implant period
Participants are monitored for safety, device performance, and study outcomes up to 6 years post-implant to assess adverse events and neural interface functionality.
Periodic follow-up visits over 6 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DEVICE_FEASIBILITY
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Alexander B Silva, Jessie R Liu, Vanessa R Anderson...
https://pubmed.ncbi.nlm.nih.gov/40343020/Sean L Metzger, Jessie R Liu, David A Moses...
https://pubmed.ncbi.nlm.nih.gov/36347863/David A Moses, Sean L Metzger, Jessie R Liu...
https://pubmed.ncbi.nlm.nih.gov/34260835/Aakash M Shah
https://pubmed.ncbi.nlm.nih.gov/40353311/Alexander B Silva, Jessie R Liu, Vanessa R Anderson...
https://pubmed.ncbi.nlm.nih.gov/40720979/Karunesh Ganguly
Lead Sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborating Sponsor